Pooran A, et al. - Through patients presenting to primary health-care facilities in four African countries (South Africa, Zambia, Zimbabwe, and Tanzania), investigators collected cost and clinical outcome data during the TB-NEAT trial. This study included 1,502 patients, and they estimated that, in a centralized laboratory, the Xpert MTB/RIF (Xpert) unit cost was much lower vs point of care, and while Xpert unit cost at point-of-care is higher, it provides good value for money vs smear microscopy. This data collected by investigators give information regarding investment and resource allocation strategies in tuberculosis-endemic settings via the current availability of point-of-care nucleic acid amplification platforms (eg, Xpert Edge).